Loading...
•
Jun 30, 2021
ResMed Q4 2021 Earnings Report
ResMed's Q4 2021 financial results demonstrated the company's strength, with revenue increasing by 14% year-over-year and diluted earnings per share at $1.33.
Key Takeaways
ResMed Inc. reported a 14% increase in revenue to $876.1 million for the fourth quarter of fiscal year 2021. Diluted earnings per share were $1.33, and non-GAAP diluted earnings per share were $1.35. The company saw recovery in core sleep apnea and COPD patient flow and benefited from a competitor's product recall.
Revenue increased by 14% to $876.1 million, or 10% on a constant currency basis.
Diluted earnings per share (EPS) reached $1.33, while non-GAAP diluted EPS was $1.35.
The quarterly dividend increased by 8% to $0.42 per share.
The company experienced recovery in core sleep apnea and COPD patient flow, alongside benefits from a competitor's product recall.
ResMed
ResMed
ResMed Revenue by Geographic Location
Revenue by Geographic Location
Europe, Asia, and other markets Revenue
CapyFin.com Forward Guidance
ResMed is confident in its ability to grow steadily through fiscal year 2022 and deliver for stakeholders by driving accelerated adoption of digital health solutions.
Positive Outlook
- Confidence in steady growth through fiscal year 2022.
- Driving accelerated adoption of digital health solutions in sleep apnea.
- Driving accelerated adoption of digital health solutions in COPD.
- Driving accelerated adoption of digital health solutions in out-of-hospital care.
- Digital health solutions provide efficiency and lower costs for providers and payers.